Effectiveness and Safety of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) among Healthcare Workers: A Seven-Month Follow-Up Study at Fifteen Central Hospitals

During a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended that they receive the COVID-19 vaccine. Our study focused on evaluating the safety and efficacy of Egypt's first approved vaccine, the Sinopharm vacci...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 11; no. 5; p. 892
Main Authors Ashmawy, Rasha, Kamal, Ehab, Amin, Wagdy, Sharaf, Sandy, Kabeel, Samar, Albiheyri, Raed, El-Maradny, Yousra A, Hassanin, Ebtisam, Elsaka, Noura, Fahmy, Ola, Awd, Ahmed, Aboeldahab, Heba, Nayle, Mai, Afifi, Magda, Ibrahim, Marwa, Rafaat, Raghda, Aly, Shahinda, Redwan, Elrashdy M
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 24.04.2023
MDPI
Subjects
Absenteeism
Adverse events
Clinical trials
Coronaviruses
COVID-19
COVID-19 vaccines
Disease
Effectiveness
Fatalities
Fever
Health aspects
Health care
healthcare workers
Hospitals
Illnesses
Immunization
Infections
Influenza
Interviews
Management
Medical personnel
Medical research
Mortality
Occupational health and safety
Pandemics
Pharmaceutical industry
Safety
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Software
vaccination
vaccine effectiveness
Vaccine efficacy
Vaccines
workdays
Workers
Egypt
COVID-19
vaccine effectiveness
SARS-CoV-2
workdays
healthcare workers
vaccination
Online AccessGet full text

Cover

Abstract During a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended that they receive the COVID-19 vaccine. Our study focused on evaluating the safety and efficacy of Egypt's first approved vaccine, the Sinopharm vaccine (BBIBP-CorV), and comparing these findings with other vaccines. An observational study was conducted in fifteen triage and isolation hospitals, from the 1st of March until the end of September 2021. The study included fully vaccinated and unvaccinated participants, and we measured vaccine effectiveness (using 1-aHR), the incidence rate of severely to critically ill hospitalized cases, COVID-19-related work absenteeism, and the safety of the vaccine as outcomes. Of the 1364 healthcare workers who were interviewed, 1228 agreed to participate. After taking the hazard ratio into account, the vaccine effectiveness was found to be 67% (95% CI, 80-43%) for symptomatic PCR-confirmed cases. The incidence rate ratio for hospitalization was 0.45 (95% CI, 0.15-1.31) in the vaccinated group compared to the unvaccinated group, and there was a significant reduction in absenteeism among the vaccinated group ( < 0.007). Most adverse events were mild and well tolerated. Vaccinated pregnant and lactating mothers did not experience any sentinel adverse events. Our study found that the BBIBP-CorV vaccine was effective in protecting healthcare workers from COVID-19.
AbstractList BACKGROUNDDuring a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended that they receive the COVID-19 vaccine. Our study focused on evaluating the safety and efficacy of Egypt's first approved vaccine, the Sinopharm vaccine (BBIBP-CorV), and comparing these findings with other vaccines. METHODSAn observational study was conducted in fifteen triage and isolation hospitals, from the 1st of March until the end of September 2021. The study included fully vaccinated and unvaccinated participants, and we measured vaccine effectiveness (using 1-aHR), the incidence rate of severely to critically ill hospitalized cases, COVID-19-related work absenteeism, and the safety of the vaccine as outcomes. RESULTSOf the 1364 healthcare workers who were interviewed, 1228 agreed to participate. After taking the hazard ratio into account, the vaccine effectiveness was found to be 67% (95% CI, 80-43%) for symptomatic PCR-confirmed cases. The incidence rate ratio for hospitalization was 0.45 (95% CI, 0.15-1.31) in the vaccinated group compared to the unvaccinated group, and there was a significant reduction in absenteeism among the vaccinated group (p < 0.007). Most adverse events were mild and well tolerated. Vaccinated pregnant and lactating mothers did not experience any sentinel adverse events. CONCLUSIONOur study found that the BBIBP-CorV vaccine was effective in protecting healthcare workers from COVID-19.
Background: During a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended that they receive the COVID-19 vaccine. Our study focused on evaluating the safety and efficacy of Egypt’s first approved vaccine, the Sinopharm vaccine (BBIBP-CorV), and comparing these findings with other vaccines. Methods: An observational study was conducted in fifteen triage and isolation hospitals, from the 1st of March until the end of September 2021. The study included fully vaccinated and unvaccinated participants, and we measured vaccine effectiveness (using 1-aHR), the incidence rate of severely to critically ill hospitalized cases, COVID-19-related work absenteeism, and the safety of the vaccine as outcomes. Results: Of the 1364 healthcare workers who were interviewed, 1228 agreed to participate. After taking the hazard ratio into account, the vaccine effectiveness was found to be 67% (95% CI, 80–43%) for symptomatic PCR-confirmed cases. The incidence rate ratio for hospitalization was 0.45 (95% CI, 0.15–1.31) in the vaccinated group compared to the unvaccinated group, and there was a significant reduction in absenteeism among the vaccinated group (p < 0.007). Most adverse events were mild and well tolerated. Vaccinated pregnant and lactating mothers did not experience any sentinel adverse events. Conclusion: Our study found that the BBIBP-CorV vaccine was effective in protecting healthcare workers from COVID-19.
During a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended that they receive the COVID-19 vaccine. Our study focused on evaluating the safety and efficacy of Egypt's first approved vaccine, the Sinopharm vaccine (BBIBP-CorV), and comparing these findings with other vaccines. An observational study was conducted in fifteen triage and isolation hospitals, from the 1st of March until the end of September 2021. The study included fully vaccinated and unvaccinated participants, and we measured vaccine effectiveness (using 1-aHR), the incidence rate of severely to critically ill hospitalized cases, COVID-19-related work absenteeism, and the safety of the vaccine as outcomes. Of the 1364 healthcare workers who were interviewed, 1228 agreed to participate. After taking the hazard ratio into account, the vaccine effectiveness was found to be 67% (95% CI, 80-43%) for symptomatic PCR-confirmed cases. The incidence rate ratio for hospitalization was 0.45 (95% CI, 0.15-1.31) in the vaccinated group compared to the unvaccinated group, and there was a significant reduction in absenteeism among the vaccinated group ( < 0.007). Most adverse events were mild and well tolerated. Vaccinated pregnant and lactating mothers did not experience any sentinel adverse events. Our study found that the BBIBP-CorV vaccine was effective in protecting healthcare workers from COVID-19.
Background: During a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended that they receive the COVID-19 vaccine. Our study focused on evaluating the safety and efficacy of Egypt’s first approved vaccine, the Sinopharm vaccine (BBIBP-CorV), and comparing these findings with other vaccines. Methods: An observational study was conducted in fifteen triage and isolation hospitals, from the 1st of March until the end of September 2021. The study included fully vaccinated and unvaccinated participants, and we measured vaccine effectiveness (using 1-aHR), the incidence rate of severely to critically ill hospitalized cases, COVID-19-related work absenteeism, and the safety of the vaccine as outcomes. Results: Of the 1364 healthcare workers who were interviewed, 1228 agreed to participate. After taking the hazard ratio into account, the vaccine effectiveness was found to be 67% (95% CI, 80–43%) for symptomatic PCR-confirmed cases. The incidence rate ratio for hospitalization was 0.45 (95% CI, 0.15–1.31) in the vaccinated group compared to the unvaccinated group, and there was a significant reduction in absenteeism among the vaccinated group ( p < 0.007). Most adverse events were mild and well tolerated. Vaccinated pregnant and lactating mothers did not experience any sentinel adverse events. Conclusion: Our study found that the BBIBP-CorV vaccine was effective in protecting healthcare workers from COVID-19.
Audience Academic
Author Sharaf, Sandy
Amin, Wagdy
Afifi, Magda
El-Maradny, Yousra A
Redwan, Elrashdy M
Fahmy, Ola
Elsaka, Noura
Nayle, Mai
Aly, Shahinda
Hassanin, Ebtisam
Kamal, Ehab
Albiheyri, Raed
Ashmawy, Rasha
Ibrahim, Marwa
Rafaat, Raghda
Aboeldahab, Heba
Awd, Ahmed
Kabeel, Samar
AuthorAffiliation 7 Centre of Excellence in Bio Nanoscience Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia
6 Biological Science Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
4 General Administration of Chest Diseases, MoHP, Cairo 11516, Egypt
1 Clinical Research Department, Maamora Chest Hospital, MoHP, Alexandria 21923, Egypt
11 Clinical Research Department, Directorate of Health Affairs, MoHP, Sharkia 71529, Egypt
3 Medical Research Division, National Research Center, Giza 12622, Egypt
14 Clinical Research Department, Kom El-Shokafa Chest Hospital, MoHP, Alexandria 21572, Egypt
5 Clinical Research Department, Directorate of Health Affairs, MoHP, Damietta 34711, Egypt
10 Clinical Pathology Department, Faculty of Medicine, New Valley University, New Valley 72713, Egypt
15 Clinical Research Department, Kafr El-Sheikh Chest Hospital, MoHP, Kafr El-Sheikh 33511, Egypt
16 Clinical Research Department, Fakous Central Hospital, MoHP, Sharkia 71529, Egypt
13 Physic
AuthorAffiliation_xml – name: 14 Clinical Research Department, Kom El-Shokafa Chest Hospital, MoHP, Alexandria 21572, Egypt
– name: 5 Clinical Research Department, Directorate of Health Affairs, MoHP, Damietta 34711, Egypt
– name: 13 Physical Therapy Department, Kafr El-Sheikh General Hospital, MoHP, Kafr El-Sheikh 33511, Egypt
– name: 1 Clinical Research Department, Maamora Chest Hospital, MoHP, Alexandria 21923, Egypt
– name: 10 Clinical Pathology Department, Faculty of Medicine, New Valley University, New Valley 72713, Egypt
– name: 8 Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt
– name: 15 Clinical Research Department, Kafr El-Sheikh Chest Hospital, MoHP, Kafr El-Sheikh 33511, Egypt
– name: 7 Centre of Excellence in Bio Nanoscience Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia
– name: 12 Egyptian Drug Authority, Alexandria 21532, Egypt
– name: 3 Medical Research Division, National Research Center, Giza 12622, Egypt
– name: 2 Infectious Diseases Administration, Directorate of Health Affairs, MoHP, Alexandria 21554, Egypt
– name: 6 Biological Science Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
– name: 4 General Administration of Chest Diseases, MoHP, Cairo 11516, Egypt
– name: 16 Clinical Research Department, Fakous Central Hospital, MoHP, Sharkia 71529, Egypt
– name: 9 Microbiology and Immunology, Faculty of Pharmacy, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Alamein 51718, Egypt
– name: 11 Clinical Research Department, Directorate of Health Affairs, MoHP, Sharkia 71529, Egypt
Author_xml – sequence: 1
  givenname: Rasha
  orcidid: 0000-0003-2689-5968
  surname: Ashmawy
  fullname: Ashmawy, Rasha
  organization: Infectious Diseases Administration, Directorate of Health Affairs, MoHP, Alexandria 21554, Egypt
– sequence: 2
  givenname: Ehab
  surname: Kamal
  fullname: Kamal, Ehab
  organization: Medical Research Division, National Research Center, Giza 12622, Egypt
– sequence: 3
  givenname: Wagdy
  surname: Amin
  fullname: Amin, Wagdy
  organization: General Administration of Chest Diseases, MoHP, Cairo 11516, Egypt
– sequence: 4
  givenname: Sandy
  surname: Sharaf
  fullname: Sharaf, Sandy
  organization: Clinical Research Department, Maamora Chest Hospital, MoHP, Alexandria 21923, Egypt
– sequence: 5
  givenname: Samar
  orcidid: 0000-0001-7509-090X
  surname: Kabeel
  fullname: Kabeel, Samar
  organization: Clinical Research Department, Directorate of Health Affairs, MoHP, Damietta 34711, Egypt
– sequence: 6
  givenname: Raed
  orcidid: 0000-0002-9739-5496
  surname: Albiheyri
  fullname: Albiheyri, Raed
  organization: Centre of Excellence in Bio Nanoscience Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia
– sequence: 7
  givenname: Yousra A
  orcidid: 0000-0001-9501-8059
  surname: El-Maradny
  fullname: El-Maradny, Yousra A
  organization: Microbiology and Immunology, Faculty of Pharmacy, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Alamein 51718, Egypt
– sequence: 8
  givenname: Ebtisam
  surname: Hassanin
  fullname: Hassanin, Ebtisam
  organization: Clinical Pathology Department, Faculty of Medicine, New Valley University, New Valley 72713, Egypt
– sequence: 9
  givenname: Noura
  surname: Elsaka
  fullname: Elsaka, Noura
  organization: Clinical Research Department, Directorate of Health Affairs, MoHP, Sharkia 71529, Egypt
– sequence: 10
  givenname: Ola
  surname: Fahmy
  fullname: Fahmy, Ola
  organization: Egyptian Drug Authority, Alexandria 21532, Egypt
– sequence: 11
  givenname: Ahmed
  surname: Awd
  fullname: Awd, Ahmed
  organization: Physical Therapy Department, Kafr El-Sheikh General Hospital, MoHP, Kafr El-Sheikh 33511, Egypt
– sequence: 12
  givenname: Heba
  surname: Aboeldahab
  fullname: Aboeldahab, Heba
  organization: Clinical Research Department, Kom El-Shokafa Chest Hospital, MoHP, Alexandria 21572, Egypt
– sequence: 13
  givenname: Mai
  surname: Nayle
  fullname: Nayle, Mai
  organization: Clinical Research Department, Kafr El-Sheikh Chest Hospital, MoHP, Kafr El-Sheikh 33511, Egypt
– sequence: 14
  givenname: Magda
  surname: Afifi
  fullname: Afifi, Magda
  organization: General Administration of Chest Diseases, MoHP, Cairo 11516, Egypt
– sequence: 15
  givenname: Marwa
  surname: Ibrahim
  fullname: Ibrahim, Marwa
  organization: Clinical Research Department, Fakous Central Hospital, MoHP, Sharkia 71529, Egypt
– sequence: 16
  givenname: Raghda
  surname: Rafaat
  fullname: Rafaat, Raghda
  organization: Clinical Research Department, Fakous Central Hospital, MoHP, Sharkia 71529, Egypt
– sequence: 17
  givenname: Shahinda
  surname: Aly
  fullname: Aly, Shahinda
  organization: Clinical Research Department, Maamora Chest Hospital, MoHP, Alexandria 21923, Egypt
– sequence: 18
  givenname: Elrashdy M
  orcidid: 0000-0001-8246-0075
  surname: Redwan
  fullname: Redwan, Elrashdy M
  organization: Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37242996$$D View this record in MEDLINE/PubMed
BookMark eNptklFvUyEYhk_MjJtz914ZEm_mxZkczjmcgzdL16yuyYzGuuodofDRUk-hAq3pf_HHSte6rItAAvl4v4e85H2ZHVlnIcteF_iiLBl-vxZSGguhKHCNW0aeZScENzQvWfnj6NH5ODsLYY7TYEXZ0uZFdlw2pCKM0ZPsz7XWIKNZQyIFJKxCI6EhbpDTaGjF9kpESNXe11Hed-OcoPHuYXR-dTW8-pKKfvwOiYWzU3QDooszKTyg787_BB8-oB4aQcLnn5yNMzRwXed-53dLNIortUEiooHREcCiPtjoRYduXFiaKLrwKnuu0wZn-_00uxtcf-vf5LefPw77vdtc1nUbc0VBsUklNWZ1sli1CooWFGmboiVSaiprQpuGKSpq3VCogQpFS6mZUhNC2vI0G-64yok5X3qzEH7DnTD8vuD8lAsfjeyAJ4IqC8x0RduqqiatTiiq8UTXRGmoE-tyx1quJgtQcufpAHp4Y82MT92aF5iQRMSJcL4nePdrBSHyhQkSuk5YcKvASUswTqvYSt8-kc7dytv0V0lVsKpum3t7e9VUJAfGapcellso7zU1Tjko8ZZ18R9VmgoWRqboaZPqBw141yC9C8GDfjBZYL5NKH-a0NTy5vHnPDT8y2P5F1rH49k
CitedBy_id crossref_primary_10_1371_journal_pone_0299747
crossref_primary_10_1371_journal_pone_0306309
crossref_primary_10_1038_s41598_024_54886_0
Cites_doi 10.1001/jama.2021.7152
10.1016/j.dsx.2021.102306
10.15585/mmwr.mm7013e3
10.3390/vaccines10030350
10.1001/jamanetworkopen.2021.42210
10.1093/jtm/taac036
10.1371/journal.pone.0281673
10.1016/j.jclinepi.2012.06.002
10.15585/mmwr.mm7034e4
10.1093/cid/ciab608
10.1186/s13613-020-00689-1
10.1200/EDBK_159514
10.1186/s12889-022-14016-9
10.1056/NEJMoa2109072
10.1038/s41467-022-30835-1
10.3389/fimmu.2022.839922
10.5578/mb.20219705
10.3390/life12091318
10.1371/journal.pone.0249038
10.1016/S2666-5247(20)30172-5
10.1056/NEJMoa2107058
10.3343/alm.2022.42.6.688
10.1186/s40249-021-00915-3
10.1001/jama.2021.23641
10.3390/ijerph192113884
10.3389/fimmu.2022.928501
10.1038/s41598-021-04665-y
10.1016/j.jinf.2021.08.031
10.3390/vaccines10081345
10.1016/j.vaccine.2022.02.039
10.1056/NEJMoa2106599
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID NPM
AAYXX
CITATION
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/vaccines11050892
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Engineering Research Database
ProQuest Central Student
Research Library Prep
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
Biological Sciences
ProQuest Research Library
ProQuest Biological Science Journals
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest - Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef
Publicly Available Content Database

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_a5fd3109f468444b8fad66f0bf52dfe5
A750996300
10_3390_vaccines11050892
37242996
Genre Journal Article
GeographicLocations Egypt
GeographicLocations_xml – name: Egypt
GroupedDBID 3V.
53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
ABUWG
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
NPM
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
AAYXX
CITATION
7T7
7XB
8FD
8FK
C1K
COVID
FR3
MBDVC
P64
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c558t-d6ed9b4cf09591348de18ed287182ccf6c526779d6a5f76e5e6ad63cf9ddb2283
IEDL.DBID RPM
ISSN 2076-393X
IngestDate Tue Oct 22 15:09:09 EDT 2024
Tue Sep 17 21:31:33 EDT 2024
Fri Oct 25 02:00:18 EDT 2024
Thu Oct 10 18:43:08 EDT 2024
Wed Apr 17 18:00:56 EDT 2024
Tue Nov 12 23:39:24 EST 2024
Thu Sep 26 17:08:56 EDT 2024
Wed Oct 16 00:38:58 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords COVID-19
vaccine effectiveness
SARS-CoV-2
workdays
healthcare workers
vaccination
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c558t-d6ed9b4cf09591348de18ed287182ccf6c526779d6a5f76e5e6ad63cf9ddb2283
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-8246-0075
0000-0002-9739-5496
0000-0003-2689-5968
0000-0001-7509-090X
0000-0001-9501-8059
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224440/
PMID 37242996
PQID 2819458728
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_a5fd3109f468444b8fad66f0bf52dfe5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10224440
proquest_miscellaneous_2820020010
proquest_journals_2819458728
gale_infotracmisc_A750996300
gale_infotracacademiconefile_A750996300
crossref_primary_10_3390_vaccines11050892
pubmed_primary_37242996
PublicationCentury 2000
PublicationDate 2023-04-24
PublicationDateYYYYMMDD 2023-04-24
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-24
  day: 24
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Vaccines (Basel)
PublicationTitleAlternate Vaccines (Basel)
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Rudenko (ref_8) 2020; 21
Zeng (ref_20) 2022; 14
Breukelen (ref_12) 2012; 65
Fowlkes (ref_21) 2021; 70
Arankalle (ref_29) 2022; 13
ref_14
Thompson (ref_19) 2021; 385
ref_11
ref_33
Lumley (ref_34) 2022; 74
Malhotra (ref_36) 2022; 5
Cucinotta (ref_1) 2020; 91
ref_30
Kim (ref_31) 2022; 42
ref_18
ref_17
ref_39
ref_38
ref_15
Liu (ref_37) 2021; 10
Pilishvili (ref_26) 2021; 385
Cevik (ref_6) 2020; 2
Khadka (ref_48) 2020; 26
Cupaiolo (ref_28) 2021; 83
Shang (ref_10) 2020; 10
(ref_23) 2022; 56
Vaishya (ref_35) 2021; 15
Thompson (ref_24) 2021; 70
AlHosani (ref_42) 2022; 40
Akar (ref_25) 2021; 55
ref_44
Kluetz (ref_13) 2016; 35
ref_41
Spitzer (ref_22) 2022; 327
ref_40
Oulhaj (ref_47) 2021; 13
ref_3
ref_2
Mousa (ref_43) 2022; 29
ref_9
Angel (ref_16) 2021; 325
Larese (ref_32) 2022; 12
Bergwerk (ref_46) 2021; 385
ref_5
ref_4
Herzberg (ref_27) 2022; 13
ref_7
Kaabi (ref_45) 2022; 13
References_xml – ident: ref_7
– volume: 325
  start-page: 2457
  year: 2021
  ident: ref_16
  article-title: Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers
  publication-title: JAMA
  doi: 10.1001/jama.2021.7152
  contributor:
    fullname: Angel
– volume: 15
  start-page: 102306
  year: 2021
  ident: ref_35
  article-title: Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers—A multicenter cohort study
  publication-title: Diabetes Metab. Syndr. Clin. Res. Rev.
  doi: 10.1016/j.dsx.2021.102306
  contributor:
    fullname: Vaishya
– volume: 70
  start-page: 495
  year: 2021
  ident: ref_24
  article-title: Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers-Eight U.S. Locations, December 2020-March 2021
  publication-title: Morb. Mortal. Wkly. Rep.
  doi: 10.15585/mmwr.mm7013e3
  contributor:
    fullname: Thompson
– ident: ref_5
– ident: ref_9
  doi: 10.3390/vaccines10030350
– volume: 5
  start-page: e2142210
  year: 2022
  ident: ref_36
  article-title: SARS-CoV-2 Reinfection Rate and Esti-mated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection among Health Care Workers in New Delhi, India
  publication-title: JAMA Netw. Open.
  doi: 10.1001/jamanetworkopen.2021.42210
  contributor:
    fullname: Malhotra
– ident: ref_3
– volume: 29
  start-page: taac036
  year: 2022
  ident: ref_43
  article-title: Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE
  publication-title: J. Travel Med.
  doi: 10.1093/jtm/taac036
  contributor:
    fullname: Mousa
– volume: 26
  start-page: 100
  year: 2020
  ident: ref_48
  article-title: Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic
  publication-title: Altern. Health Med.
  contributor:
    fullname: Khadka
– volume: 91
  start-page: 157
  year: 2020
  ident: ref_1
  article-title: WHO declares COVID-19 a pandemic
  publication-title: Acta Biomed.
  contributor:
    fullname: Cucinotta
– ident: ref_18
  doi: 10.1371/journal.pone.0281673
– ident: ref_39
– ident: ref_40
– volume: 65
  start-page: 1212
  year: 2012
  ident: ref_12
  article-title: Calculating sample sizes for cluster randomized trials: We can keep it simple and efficient!
  publication-title: J. Clin. Epidemiol.
  doi: 10.1016/j.jclinepi.2012.06.002
  contributor:
    fullname: Breukelen
– volume: 70
  start-page: 1167
  year: 2021
  ident: ref_21
  article-title: Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B. 1.617. 2 (Delta) variant predominance-eight US locations, December 2020-August 2021
  publication-title: Morb. Mortal. Wkly. Rep.
  doi: 10.15585/mmwr.mm7034e4
  contributor:
    fullname: Fowlkes
– volume: 74
  start-page: 1208
  year: 2022
  ident: ref_34
  article-title: An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciab608
  contributor:
    fullname: Lumley
– volume: 10
  start-page: 73
  year: 2020
  ident: ref_10
  article-title: Management of critically ill patients with COVID-19 in ICU: Statement from front-line intensive care experts in Wuhan, China
  publication-title: Ann. Intensiv. Care
  doi: 10.1186/s13613-020-00689-1
  contributor:
    fullname: Shang
– ident: ref_14
– volume: 35
  start-page: 67
  year: 2016
  ident: ref_13
  article-title: Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
  publication-title: Am. Soc. Clin. Oncol. Educ. Book.
  doi: 10.1200/EDBK_159514
  contributor:
    fullname: Kluetz
– ident: ref_44
  doi: 10.1186/s12889-022-14016-9
– volume: 385
  start-page: 1474
  year: 2021
  ident: ref_46
  article-title: COVID-19 Breakthrough Infections in Vaccinated Health Care Workers
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2109072
  contributor:
    fullname: Bergwerk
– volume: 13
  start-page: 3215
  year: 2022
  ident: ref_45
  article-title: Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-30835-1
  contributor:
    fullname: Kaabi
– volume: 13
  start-page: 839922
  year: 2022
  ident: ref_27
  article-title: Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.839922
  contributor:
    fullname: Herzberg
– volume: 55
  start-page: 519
  year: 2021
  ident: ref_25
  article-title: Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers
  publication-title: Mikrobiyol Bul.
  doi: 10.5578/mb.20219705
  contributor:
    fullname: Akar
– volume: 21
  start-page: 2
  year: 2020
  ident: ref_8
  article-title: A promising inactivated whole-virion SARS-CoV-2 vaccine
  publication-title: Lancet Infect Dis.
  contributor:
    fullname: Rudenko
– ident: ref_33
  doi: 10.3390/life12091318
– ident: ref_4
– ident: ref_11
  doi: 10.1371/journal.pone.0249038
– ident: ref_2
– volume: 13
  start-page: 3215
  year: 2021
  ident: ref_47
  article-title: Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
  publication-title: Lancet Respir. Med.
  contributor:
    fullname: Oulhaj
– volume: 2
  start-page: e13
  year: 2020
  ident: ref_6
  article-title: SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: A systematic review and meta-analysis
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(20)30172-5
  contributor:
    fullname: Cevik
– volume: 385
  start-page: 320
  year: 2021
  ident: ref_19
  article-title: Prevention and Attenuation of COVID-19 with the BNT162b2 and mRNA-1273 Vaccines
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2107058
  contributor:
    fullname: Thompson
– volume: 42
  start-page: 688
  year: 2022
  ident: ref_31
  article-title: Immunogenicity of third-dose BNT162b2 mRNA vac-cine following two doses of ChAdOx1 in health care workers: A prospective longitudinal study
  publication-title: Ann. Lab. Med.
  doi: 10.3343/alm.2022.42.6.688
  contributor:
    fullname: Kim
– volume: 10
  start-page: 421
  year: 2021
  ident: ref_37
  article-title: Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis
  publication-title: Infect. Dis. Poverty
  doi: 10.1186/s40249-021-00915-3
  contributor:
    fullname: Liu
– volume: 327
  start-page: 341
  year: 2022
  ident: ref_22
  article-title: Association of a Third Dose of BNT162b2 Vaccine with Incidence of SARS-CoV-2 Infection among Health Care Workers in Israel
  publication-title: JAMA
  doi: 10.1001/jama.2021.23641
  contributor:
    fullname: Spitzer
– ident: ref_30
  doi: 10.3390/ijerph192113884
– ident: ref_41
– ident: ref_15
– volume: 56
  start-page: 36
  year: 2022
  ident: ref_23
  article-title: Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study
  publication-title: Mikrobiyol. Bul.
– volume: 13
  start-page: 928501
  year: 2022
  ident: ref_29
  article-title: Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.928501
  contributor:
    fullname: Arankalle
– volume: 12
  start-page: 2533
  year: 2022
  ident: ref_32
  article-title: Incidence of COVID-19 infection in hospital workers from March 1, 2020 to May 31, 2021 routinely tested, before and after vaccination with BNT162B2
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-04665-y
  contributor:
    fullname: Larese
– ident: ref_38
– volume: 14
  start-page: 637
  year: 2022
  ident: ref_20
  article-title: Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
  publication-title: Sci. Transl. Med.
  contributor:
    fullname: Zeng
– volume: 83
  start-page: 559
  year: 2021
  ident: ref_28
  article-title: Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2021.08.031
  contributor:
    fullname: Cupaiolo
– ident: ref_17
  doi: 10.3390/vaccines10081345
– volume: 40
  start-page: 2003
  year: 2022
  ident: ref_42
  article-title: Impact of the Sinopharm ’ s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2022.02.039
  contributor:
    fullname: AlHosani
– volume: 385
  start-page: e90
  year: 2021
  ident: ref_26
  article-title: Effectiveness of mRNA COVID-19 Vaccine among U.S. Health Care Personnel
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2106599
  contributor:
    fullname: Pilishvili
SSID ssj0000913867
Score 2.3090284
Snippet During a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended that they...
Background: During a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended...
BACKGROUNDDuring a pandemic, healthcare workers are at high risk of contracting COVID-19. To protect these important individuals, it is highly recommended that...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 892
SubjectTerms Absenteeism
Adverse events
Clinical trials
Coronaviruses
COVID-19
COVID-19 vaccines
Disease
Effectiveness
Fatalities
Fever
Health aspects
Health care
healthcare workers
Hospitals
Illnesses
Immunization
Infections
Influenza
Interviews
Management
Medical personnel
Medical research
Mortality
Occupational health and safety
Pandemics
Pharmaceutical industry
Safety
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Software
vaccination
vaccine effectiveness
Vaccine efficacy
Vaccines
workdays
Workers
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hnrgg3pgWNEioUKlWk315zS2tiAISKCJN1Ju13ofai1M1blH-Cz-WGdtJYzhw4bq7lrw7szPf7Mx-y9j7PA-ZjVqk6B1sKqOLKeLmkEarSqODz4aRbiN_-64nc_n1Ql3sPPVFNWEtPXC7cCdWRU_slVFqI6UsTbRe6zgoo-I-hpa9dJDvBFONDc6HwuiszUsKjOtP7qyjTPUK3R1ikpz3_FBD1_-3Ud7xSv2KyR0XNH7MHnXYEUbtPz9hD0L1lB1OW_Lp9TGc39-lWh3DIUzvaanXz9ivlqi4s25gKw8zG0O9hmWELxVdcLhD4Imtox-z9Gy5SDks2unAR4yWT6fYeLM4guZ9IphsC8eADtwRRX6CEcyIECpFQ1FfwhhVbPkznV8DFSuuwdYwvoo1Bs7QnSnD5tWS1XM2H38-P5uk3dsMqVPK1KlHOealdJHOEYdCGh-GJniKvwx3LmqnuM6y3GsUYKaDChrlJlzMvS-JcucF26uWVXjFQHnjB0NnB9wh1lDWcCtUKUS0QuZGi4QdbSRVXLcUHAWGLiTV4k-pJuyURLkdR-TZTQOqVNGpVPEvlUrYB1KEgrY4Loaz3U0F_F0iyypGhLJy4ipL2EFvJG5N1-_eqFLRmYZVQZlLqUzGTcLebbvpSyp3q8LylsZQ7QzF6wl72Wredkoi44QhdMJMTyd7c-73VFeXDXF4Qx8o5eD1_1ilffaQI-CjzBqXB2yvvrkNbxCg1eXbZi_-BnofO78
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Coronavirus Research Database
  dbid: COVID
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLage-GF-yUwkJHQYNK8tY7tOLygrlB1SEBF12pvkeMLm5CS0qZD5bfwY_HJpV2GxAOvtiPZ0edz93cQehXHNlJOhMRrB0WY0454u9kSp3gqhTVRz8Fr5E-fxWjKPp7xszrgtqzLKhuZWApqk2uIkR9BwodxGVH5bv6DQNcoyK7WLTRuop1Qcio7aGfwZXbyfhNlAdZLKaIqPxl6__7oUmnIWC-92vO2SUxb-qik7f9bOF_RTu3KySuqaHgHJc0hqgqU74erIj3Uv67xO_7_Ke-i27WVivsVrO6hGza7j_bGFc31-gCfbl9tLQ_wHh5vCbDXD9DvihK5lqNYZQZPlLPFGucOn2TwlOLSm7h-tP91Qgb5jFA8q34YfuP98uOxH1zM9nHZCQmPNiVqGEL73l59i_t4AtRTxIuk4hwPPZjzn2Q6x1AWucaqwMMLV3gXHdfRa9z0R1k-RNPhh9PBiNRdIIjmXBbEeMTEKdMOIpa9kElje9Ia8PQk1doJzamIotgIxV0kLLdCGRFqFxuTArnPI9TJ8sw-QZgbabo9rbpUe6uGK0lVyNMwdCpksRRhgPYbLCTziuwj8U4S4Ca5jpsAHQNYNuuAprscyBffkvrWJ35HBqhXHROSMZZK57cmXDd1nBpneYBeA9QSECb-Z2hVv4nw2wVarqQP9lwMrGgB2m2t9EJAt6cbPCW1EFomWzAF6OVmGr6EwrrM5itYA1U6EBkI0OMK25sjhREFa0UESLZQ3zpzeya7OC8pykuiQsa6T_-9r2foFvVGI2TnKNtFnWKxss-9kVekL-qb_AfMIFbG
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1bb9MwFLbQkNBeEHcCAxkJDSbNrI0vcZAQ6iaqggSq6FrtLXJ8YZNQMtps0P_Cj-WcJG0XGK-2E9k-d_v4O4S8TFOfmKA4A-tgmAg2MPCbPQtG5lp5l_QDvkb-_EWNpuLTiTzZPI9uN3BxbWiH9aSm8-9vfv1YvgeBf4cRJ4TsB5fG4iX0AiwZuBspKOSbsYA4HRP5Wme_1stpn-u6pGwMwTvjKT9p7i2v_ck2ucWTGLW16pisGtn_X_19xYB1kyuvWKvhHXK7dTPpoOGLu-SGL-6R3XGDU73cp8ebZ1eLfbpLxxsE6-V98rvBNG4VITWFoxMTfLWkZaAfC3wLcQk-KrQOvk7YUTljMZ01K6OvIbA-HEPjfLZH61JGdLTOMaN4Ng8O51s6oBPEjmKgU6pTOgRuLH-y6TnFvMYlNRUdnoUKYmzaHj_TVYGTxQMyHX44PhqxtowDs1LqijkgeZoLG_DIsc-Fdr6vvcNQTcfWBmVlrJIkdcrIkCgvvTJOcRtS53JE53lItoqy8I8JlU67Xt-aXmzBLZFGx4bLnPNguEi14hHZW1EqO2_QOjKIcpDA2d8EjsghknI9DnG264Zy_i1rxTaDGTnETg1CaSFErgNMTYVeHmTsgpcReYWMkCF_wmZY0z5qgOkirlY2QIcsRViziOx0RoIU2273ipWylRBkeMkppE5iHZEX6278EjPjCl9e4BhMs8HQPiKPGs5bL2nFwBHRHZ7srLnbU5yd1hjjNdKgEL0n__3pU7Idg8OHN2ux2CFb1fzCPwMHrcqf13L3B3nZOIE
  priority: 102
  providerName: Scholars Portal
Title Effectiveness and Safety of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) among Healthcare Workers: A Seven-Month Follow-Up Study at Fifteen Central Hospitals
URI https://www.ncbi.nlm.nih.gov/pubmed/37242996
https://www.proquest.com/docview/2819458728
https://search.proquest.com/docview/2820020010
https://pubmed.ncbi.nlm.nih.gov/PMC10224440
https://doaj.org/article/a5fd3109f468444b8fad66f0bf52dfe5
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa28cIL4k5gVEZCg0nL2iax4_DWllUdUke1rtXeIscXVoklVZsN9b_wYzknl66BN14SyXYkO-dun_OZkI9RZEJpue-CdZBuYJV1wW82rpUsEdzosGuxGnl8wUez4Ns1u94jvK6FKZL2VbI4TX_enqaLmyK3cnmr2nWeWHsyHhQwaEHQae-TfeDQnRi90L9R1xc8LM8kfYjp2_dS4Sn1Gkwd-CMR3mDjhx5qYt4wRwVq_7-6ecc4NRMndyzR8Cl5UrmQtFdO9RnZM-lzcjQpMag3J_TqoaRqfUKP6OQBnXrzgvwu8YorJUdlqulUWpNvaGbpeYp1Dvfgf0Jr73LqDrK569F5uTL6GYLm_gQaV_NjWlxTREfb_DGK--7gTH6hPTpFXCgX9EV-Q4fAadkvd7akmLO4oTKnw4XNIX6m1dYyrS8vWb8ks-HZ1WDkVlc0uIoxkbsayBklgbK4ndj1A6FNVxiNYZjwlLJcMY-HYaS5ZDbkhhkuNfeVjbROEHnnFTlIs9S8IZRpoTtdJTueAuIyKTzps8T3rfSDSHDfIcc1peJlicQRQwSDBI7_JrBD-kjK7TjE0C4astWPuOKkGGakERfVBlwANyXCwtS47SSWedoa5pBPyAgxSjr8DCWrggWYLmJmxT10tiKELHPIYWMkSKhqdtesFFcaYh3jAWbAROgJh3zYduOXmPWWmuwOx2AKDYbtDnldct52STUDO0Q0eLKx5mYPiFOBH16Lz9v___QdeeyBt4fHal5wSA7y1Z15D95ZnrTIo_7ZxeQS3oPv8_OvrWKXA57jQLQKQf0DZKJAlQ
link.rule.ids 230,315,730,783,787,867,888,2109,2228,21400,24330,27936,27937,33756,33757,38528,43817,43907,53804,53806,74630,74740
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZge4AXxJ3AACOhwaRZaxPbcXhB7bSqg62q1ov2Fjm-sL0kpc2G-l_4sZzTpO0CEq-2I9k5x-fu7xDyMUlcrL2MGGgHzbg3noHd7JjXIlPS2bjt8TXy-UD2J_zbpbisA26LuqxyLRNXgtoWBmPkR5jw4ULFofo6-8mwaxRmV-sWGvfJLkJVgfO12z0ZDC82URZEvVQyrvKTEfj3R7faYMZ6AWoPbJMkbOijFWz_v8L5jnZqVk7eUUW9x-RRbUPSTkX0J-Sey5-S_WEFQr08pOPtm6rFId2nwy089fIZ-V0BFtdSjurc0pH2rlzSwtPTHB863IIBCqOdixE7LqYspNPqOPQzeM3dIQzOpwd01aeI9jcFZBQD72BNfqEdOkJgKAYCo7yiPWC14hebzCgWLS6pLmnv2pfgQNM6tkzX3UsWz8mkdzI-7rO6RwMzQqiSWaBnknHjMZ7Yjriyrq2cRT9MhcZ4aUQo4zixUgsfSyec1FZGxifWZgi984Ls5EXuXhEqrLKtttGt0IDNIbQKdSSyKPI64omSUUAO1pRKZxUURwouDFI1_ZuqAekiKTfrEER7NVDMf6T1nUxhRxaBUT2XinOeKQ9bk76VeRFa70RAPiEjpHjV4WcYXb9YgO0iaFbaQWsrQcyygOw1VsIVNc3pNSultYhYpFuGDsiHzTR-iWVvuStucA3W0KDfHpCXFedtjhTFIdoSMiCqwZONMzdn8uurFYD4CkaQ89br_-_rPXnQH5-fpWeng-9vyMMQzDvMo4V8j-yU8xv3FsyxMntX37k_mpg2vw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLagkxAviPsCA4yEBpMWtU1sx-EFtWNVx6Wq1q3aW-T4wvaSlDYb6n_hx3JO47YLSLzajmTn3I-Pv0PIuzS1iXIiDsE6qJA57ULwm23oFM-lsCbpOnyN_H0khufsywW_8PVPC19WudaJK0VtSo058jZe-DAuk0i2nS-LGH8efJr9DLGDFN60-nYad8lOwkTcaZGd_vFofLrJuCACphRJfVcZQ6zfvlEab68XYALBT0mjhm1aQfj_q6hvWapmFeUtszR4SB54f5L2agZ4RO7Y4jHZH9eA1MtDerZ9X7U4pPt0vIWqXj4hv2vwYq_xqCoMnShnqyUtHT0p8NHDDTijMNo7nYRH5TSM6LQ-Dv0AEXR_DIPz6QFd9Syiw00xGcUkPHiWH2mPThAkKgTlUV3SAbBd-Ss8n1EsYFxSVdHBlasgmKY-z0zXnUwWT8n54PjsaBj6fg2h5lxWoQHapjnTDnOL3ZhJY7vSGozJZKS1E5pHIklSIxR3ibDcCmVErF1qTI4wPM9IqygLu0soN9J0ulp1Ig3-B1cyUjHP49ipmKVSxAE5WFMqm9WwHBmEM0jV7G-qBqSPpNysQ0Dt1UA5_5F5-cxgRwZBUh0TkjGWSwdbE66TOx4ZZ3lA3iMjZCj28DO08q8XYLsIoJX10PNKEb8sIHuNlSCuujm9ZqXMq4tFtmXugLzdTOOXWAJX2PIa12A9DcbwAXlec97mSHESoV8hAiIbPNk4c3OmuLpcgYmvIAUZ67z4_77ekHsgbtm3k9HXl-R-BJ4eXqlFbI-0qvm1fQWeWZW_9iL3BxdxOu0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+and+Safety+of+Inactivated+SARS-CoV-2+Vaccine+%28BBIBP-CorV%29+among+Healthcare+Workers%3A+A+Seven-Month+Follow-Up+Study+at+Fifteen+Central+Hospitals&rft.jtitle=Vaccines+%28Basel%29&rft.au=Ashmawy%2C+Rasha&rft.au=Kamal%2C+Ehab&rft.au=Amin%2C+Wagdy&rft.au=Sharaf%2C+Sandy&rft.date=2023-04-24&rft.issn=2076-393X&rft.volume=11&rft.issue=5&rft_id=info:doi/10.3390%2Fvaccines11050892&rft_id=info%3Apmid%2F37242996&rft.externalDocID=37242996
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon